AU2001293555A1 - Benzoic acid derivatives and uses thereof - Google Patents

Benzoic acid derivatives and uses thereof

Info

Publication number
AU2001293555A1
AU2001293555A1 AU2001293555A AU9355501A AU2001293555A1 AU 2001293555 A1 AU2001293555 A1 AU 2001293555A1 AU 2001293555 A AU2001293555 A AU 2001293555A AU 9355501 A AU9355501 A AU 9355501A AU 2001293555 A1 AU2001293555 A1 AU 2001293555A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
alkenyl
halogen
coo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293555A
Other languages
English (en)
Inventor
Dominique Cheneval
Tania Kastelic
Albert Leutwiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novation Pharmaceuticals Inc
Original Assignee
Novation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novation Pharmaceuticals Inc filed Critical Novation Pharmaceuticals Inc
Publication of AU2001293555A1 publication Critical patent/AU2001293555A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001293555A 2000-09-21 2001-09-21 Benzoic acid derivatives and uses thereof Abandoned AU2001293555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2320664 2000-09-21
CA2320664 2000-09-21
PCT/CA2001/001331 WO2002024674A1 (en) 2000-09-21 2001-09-21 Benzoic acid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
AU2001293555A1 true AU2001293555A1 (en) 2002-04-02

Family

ID=4167219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293555A Abandoned AU2001293555A1 (en) 2000-09-21 2001-09-21 Benzoic acid derivatives and uses thereof

Country Status (8)

Country Link
US (1) US20050049202A1 (de)
EP (1) EP1318991B1 (de)
JP (1) JP2004509167A (de)
AT (1) ATE336487T1 (de)
AU (1) AU2001293555A1 (de)
DE (1) DE60122350T2 (de)
ES (1) ES2276829T3 (de)
WO (1) WO2002024674A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
KR101310883B1 (ko) * 2006-03-29 2013-09-25 삼성에스디아이 주식회사 다공성 금속 산화물 및 그 제조방법
US7597914B1 (en) * 2007-10-02 2009-10-06 Allen Jay Cohen Ala-septic pre-cancerous liquid dissolving solution and method
US8153171B1 (en) * 2007-10-02 2012-04-10 Allen Jay Cohen Solution for dissolving pre-melanoma lesions and melanoma lesions including psoriasis, herpes simplex lesions and eczema lesions
KR101217066B1 (ko) 2010-06-29 2012-12-31 서울대학교산학협력단 벤조산 유도체를 포함하는, 간경변의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE36477E (en) * 1988-03-29 1999-12-28 Taiho Pharmaceutical Co., Ltd. Benzoic acid derivatives and process for preparing the same
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
EP0875246A1 (de) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmazeutische Zusammensetzung aus Ascorbinsäurederivate zur Behandlung von Krebs

Also Published As

Publication number Publication date
DE60122350D1 (de) 2006-09-28
WO2002024674A1 (en) 2002-03-28
ATE336487T1 (de) 2006-09-15
EP1318991B1 (de) 2006-08-16
DE60122350T2 (de) 2007-12-06
ES2276829T3 (es) 2007-07-01
US20050049202A1 (en) 2005-03-03
EP1318991A1 (de) 2003-06-18
JP2004509167A (ja) 2004-03-25

Similar Documents

Publication Publication Date Title
US6635671B1 (en) Compounds which affect mRNA stability and uses therefor
RU2730503C2 (ru) Терапевтическое средство для лечения рака молочной железы
CN114315754B (zh) 一种异羟肟酸类化合物及其用途
HUT65910A (en) Process for preparing oxygen containing macrocyclic organic compounds
EP0091795A1 (de) Olefinische Benzimidazole
EP1318991B1 (de) Benzoesaüre derivate und deren verwendung
KR20110137868A (ko) Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
EP3679930A1 (de) Therapeutikum für fettlebererkrankungen und therapeutikum für adipositas
JP3990477B2 (ja) 神経分化誘導剤
US5023261A (en) Acylated benzofuro[3,2-c]quinoline compounds with utility as treatments for osteoporosis
KR100407849B1 (ko) 헬리코박터의감염에기인하는질환의치료제
JPH0559038A (ja) チオウレア誘導体及びこれを含有する医薬製剤
JPS6239564A (ja) α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体
CA2420185A1 (en) Benzoic acid derivatives and uses thereof
WO2013085340A1 (ko) 바이사이클릭 피리디놀 유도체를 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물
US11576892B2 (en) Benzopyran derivatives and uses thereof
DE69916571T2 (de) Hemmer der angiogenese und der urokinase produktion und seine medizinische anwendung
JPH08217672A (ja) キサントン誘導体を含有する抗ヘリコバクター・ピロリ薬
CZ312592A3 (en) Bis(phenyl)ethane derivatives, process of their preparation and pharmaceutical composition in which said derivatives are comprised
EP0293146A1 (de) Benzofuro[3,2-c]quinolinverbindungen
CN110283138B (zh) 化合物、该化合物的制备方法及该化合物的应用和应用该化合物的产品
JPH0356417A (ja) 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類
KR20230037853A (ko) 췌장암의 예방 또는 치료용 조성물
Kuo et al. Some immunomodulatory principles isolated from piper kadsura
CN110229146A (zh) 组蛋白去乙酰化酶抑制剂及其制备方法与用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application